239 related articles for article (PubMed ID: 8723643)
1. The amino terminal domain of the glucagon-like peptide-1 receptor is a critical determinant of subtype specificity.
Graziano MP; Hey PJ; Strader CD
Recept Channels; 1996; 4(1):9-17. PubMed ID: 8723643
[TBL] [Abstract][Full Text] [Related]
2. The isolated N-terminal domain of the glucagon-like peptide-1 (GLP-1) receptor binds exendin peptides with much higher affinity than GLP-1.
López de Maturana R; Willshaw A; Kuntzsch A; Rudolph R; Donnelly D
J Biol Chem; 2003 Mar; 278(12):10195-200. PubMed ID: 12524435
[TBL] [Abstract][Full Text] [Related]
3. A model for receptor-peptide binding at the glucagon-like peptide-1 (GLP-1) receptor through the analysis of truncated ligands and receptors.
Al-Sabah S; Donnelly D
Br J Pharmacol; 2003 Sep; 140(2):339-46. PubMed ID: 12970080
[TBL] [Abstract][Full Text] [Related]
4. High potency antagonists of the pancreatic glucagon-like peptide-1 receptor.
Montrose-Rafizadeh C; Yang H; Rodgers BD; Beday A; Pritchette LA; Eng J
J Biol Chem; 1997 Aug; 272(34):21201-6. PubMed ID: 9261127
[TBL] [Abstract][Full Text] [Related]
5. Met-204 and Tyr-205 are together important for binding GLP-1 receptor agonists but not their N-terminally truncated analogues.
López de Maturana R; Treece-Birch J; Abidi F; Findlay JB; Donnelly D
Protein Pept Lett; 2004 Feb; 11(1):15-22. PubMed ID: 14965274
[TBL] [Abstract][Full Text] [Related]
6. Residues within the transmembrane domain of the glucagon-like peptide-1 receptor involved in ligand binding and receptor activation: modelling the ligand-bound receptor.
Coopman K; Wallis R; Robb G; Brown AJ; Wilkinson GF; Timms D; Willars GB
Mol Endocrinol; 2011 Oct; 25(10):1804-18. PubMed ID: 21868452
[TBL] [Abstract][Full Text] [Related]
7. Different domains of the glucagon and glucagon-like peptide-1 receptors provide the critical determinants of ligand selectivity.
Runge S; Wulff BS; Madsen K; Bräuner-Osborne H; Knudsen LB
Br J Pharmacol; 2003 Mar; 138(5):787-94. PubMed ID: 12642379
[TBL] [Abstract][Full Text] [Related]
8. The major determinant of exendin-4/glucagon-like peptide 1 differential affinity at the rat glucagon-like peptide 1 receptor N-terminal domain is a hydrogen bond from SER-32 of exendin-4.
Mann RJ; Nasr NE; Sinfield JK; Paci E; Donnelly D
Br J Pharmacol; 2010 Aug; 160(8):1973-84. PubMed ID: 20649595
[TBL] [Abstract][Full Text] [Related]
9. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.
Baggio LL; Huang Q; Brown TJ; Drucker DJ
Gastroenterology; 2004 Aug; 127(2):546-58. PubMed ID: 15300587
[TBL] [Abstract][Full Text] [Related]
10. The glucagon-like peptide-1 receptor binding site for the N-terminus of GLP-1 requires polarity at Asp198 rather than negative charge.
López de Maturana R; Donnelly D
FEBS Lett; 2002 Oct; 530(1-3):244-8. PubMed ID: 12387900
[TBL] [Abstract][Full Text] [Related]
11. The primary ligand-binding interaction at the GLP-1 receptor is via the putative helix of the peptide agonists.
Al-Sabah S; Donnelly D
Protein Pept Lett; 2004 Feb; 11(1):9-14. PubMed ID: 14965273
[TBL] [Abstract][Full Text] [Related]
12. The isolated N-terminal extracellular domain of the glucagon-like peptide-1 (GLP)-1 receptor has intrinsic binding activity.
Wilmen A; Göke B; Göke R
FEBS Lett; 1996 Nov; 398(1):43-7. PubMed ID: 8946950
[TBL] [Abstract][Full Text] [Related]
13. Glucagon and glucagon-like peptide 1: selective receptor recognition via distinct peptide epitopes.
Hjorth SA; Adelhorst K; Pedersen BB; Kirk O; Schwartz TW
J Biol Chem; 1994 Dec; 269(48):30121-4. PubMed ID: 7527026
[TBL] [Abstract][Full Text] [Related]
14. Localization of the domains involved in ligand binding and activation of the glucose-dependent insulinotropic polypeptide receptor.
Gelling RW; Wheeler MB; Xue J; Gyomorey S; Nian C; Pederson RA; McIntosh CH
Endocrinology; 1997 Jun; 138(6):2640-3. PubMed ID: 9165060
[TBL] [Abstract][Full Text] [Related]
15. Exchange of W39 by A within the N-terminal extracellular domain of the GLP-1 receptor results in a loss of receptor function.
Van Eyll B; Göke B; Wilmen A; Göke R
Peptides; 1996; 17(4):565-70. PubMed ID: 8804062
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis.
Li Y; Hansotia T; Yusta B; Ris F; Halban PA; Drucker DJ
J Biol Chem; 2003 Jan; 278(1):471-8. PubMed ID: 12409292
[TBL] [Abstract][Full Text] [Related]
17. Effects of intracerebroventricular injection of glucagon like peptide-1 and its related peptides on serotonin metabolism and on levels of amino acids in the rat hypothalamus.
Owji AA; Khoshdel Z; Sanea F; Panjehshahin MR; Shojaee Fard M; Smith DM; Coppock HA; Ghatei MA; Bloom SR
Brain Res; 2002 Mar; 929(1):70-5. PubMed ID: 11852032
[TBL] [Abstract][Full Text] [Related]
18. Roles of specific extracellular domains of the glucagon receptor in ligand binding and signaling.
Unson CG; Wu CR; Jiang Y; Yoo B; Cheung C; Sakmar TP; Merrifield RB
Biochemistry; 2002 Oct; 41(39):11795-803. PubMed ID: 12269822
[TBL] [Abstract][Full Text] [Related]
19. Black widow spider alpha-latrotoxin: a presynaptic neurotoxin that shares structural homology with the glucagon-like peptide-1 family of insulin secretagogic hormones.
Holz GG; Habener JF
Comp Biochem Physiol B Biochem Mol Biol; 1998 Oct; 121(2):177-84. PubMed ID: 9972293
[TBL] [Abstract][Full Text] [Related]
20. GLP-1/GIP chimeric peptides define the structural requirements for specific ligand-receptor interaction of GLP-1.
Gallwitz B; Witt M; Morys-Wortmann C; Fölsch UR; Schmidt WE
Regul Pept; 1996 May; 63(1):17-22. PubMed ID: 8795084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
